Minister gets two journalists imprisoned for reporting theft in his house

The Togolese authorities should release Loic Lawson and Anani Sossou from prison and drop all charges against the journalists who are being abused at the instance of a Minister of State.

Lawson, the editor of “Flambeau des Democrates”, and Sossou, a freelancer, were incarcerated on November 15, 2023, following a defamation complaint by Housing Minister Kodjo Adedze.

The two journalists separately claimed on social media that a sum of 400 million FCFA (a little over 600,000 USD) had been stolen from the Minister’s residence. While the minister has himself reported the burglary to the police without disclosing the amount involved, he avers that the sum mentioned by the journalists was exaggerated and intended to cause him public disaffection.

This is the second time in eight months that journalists have been detained over defamation complaints by government officials. In March, two journalists were sentenced in absentia to three years imprisonment after they had been previously detained over complaints from two Ministers. Another journalist, Joel Egah, who was being tried alongside the two died a few days before the sentence which followed a trial for “publishing false information on social networks” and “insulting authority” upon complaints from the Minister of Commerce, Kodzo Adedze and the Minister of Justice, Pius Agbetomey.

Under Togo’s media law, defamation has been decriminalized. However, the law does not cover social media, so alleged media offences committed on online platforms are prosecuted under the criminal code or digital code.

Meanwhile, the Dynamique pour la majorite du Peuple (DMP), a grouping of Togo’s opposition parties, has condemned the imprisonment of the two journalists and demanded a review of the country’s media code.

“The DMP is of the view that the new digital code which conflates a professional journalist with a social media activist, subjecting them to the same legal rules in case of a court action, constitutes a major regression and a violation of press freedom which had been obtained through an arduous struggle by the Togolese people.”

The Media Foundation for West Africa also condemns the arbitrary imprisonment of Lawson and Sossou and demands their immediate release. We urge the Togolese judiciary to resist pressure from the executive and defend press freedom

Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials

Collaboration leverages Medidata AI to improve access and participation of diverse population groups in clinical studies

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced a partnership with Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.

Fortrea’s use of Medidata AI builds on an existing collaboration between the two companies, expanding on Fortrea’s use of Medidata Rave EDC, an advanced, robust, and secure EDC system for clinical trial site, patient and lab data capture and management. Fortrea will leverage features of Medidata AI Intelligent Trials, including study feasibility and diversity data, to help emerging and large biopharmas, as well as medical device and diagnostic companies, achieve enrollment goals that reflect the populations most impacted by each disease or condition under study.

“Medidata’s data and interface capabilities will enhance our ability to seamlessly integrate diverse populations into the clinical trial process,” said Fortrea COO and President of Clinical Services Mark Morais. “We are thrilled to work with Medidata as part of Fortrea’s go-forward data strategy.”

“Fortrea and Medidata share a commitment to advancing clinical trial research and this partnership is poised to reshape the landscape of diversity in clinical trials globally,” said Fareed Melhem, SVP, Medidata AI. “Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of approximately 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Jennifer Minx (Media) – 919-410-4195, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
Hima Inguva (Investors) – 877-495-0816, Investors@fortrea.com

GlobeNewswire Distribution ID 8981816

Fortrea annonce un partenariat avec Medidata basé sur l’IA afin d’accroître la diversité dans les essais cliniques

La collaboration s’appuie sur l’IA de Medidata pour améliorer l’accès et la participation de divers groupes de population aux études cliniques

DURHAM, Caroline du Nord, 20 nov. 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), l’un des plus grands organismes de recherche sous contrat (« ORC ») au monde, a annoncé aujourd’hui un partenariat avec Medidata, une société de Dassault Systèmes et l’un des principaux fournisseurs de solutions d’essais cliniques pour le secteur des sciences de la vie, afin d’utiliser les essais de Medidata basés sur l’intelligence artificielle pour améliorer l’accès à divers patients aux essais cliniques menés par Fortrea.

L’utilisation de l’IA de Medidata par Fortrea s’inscrit dans le cadre d’une collaboration déjà existante entre les deux sociétés, en élargissant l’utilisation par Fortrea de Rave EDC de Medidata, un système EDC avancé, robuste et sécurisé pour la saisie et la gestion des données relatives aux centres d’essais cliniques, aux patients et aux laboratoires. Fortrea exploitera les fonctionnalités des essais alimentés par l’IA de Medidata, y compris les données de faisabilité et de diversité des études, afin d’aider les entreprises biopharmaceutiques (qu’elles soient nouvelles ou de grande taille), ainsi que les sociétés proposant des dispositifs médicaux et des diagnostics, à atteindre des objectifs de participation aux études cliniques qui soient à l’image des populations les plus impactées par chaque maladie ou situation étudiée.

« Les données et les capacités d’interface de Medidata amélioreront notre capacité à intégrer de manière transparente diverses populations dans les processus d’essais cliniques », a déclaré Mark Morais, directeur des opérations et président des services cliniques de Fortrea. « Nous sommes ravis de travailler avec Medidata dans le cadre de la stratégie de Fortrea en matière de données. »

« Fortrea et Medidata partagent le même engagement à faire avancer la recherche sur les essais cliniques et ce partenariat est destiné à remodeler le paysage de la diversité dans les essais cliniques à l’échelle mondiale », a déclaré Fareed Melhem, vice-président principal, Medidata AI. « Les solutions que nous développons ensemble aident les clients spécialisés dans les sciences de la vie à réduire les délais de réalisation des études et à rendre les bienfaits des thérapies cliniques plus accessibles à un large éventail d’individus. »

À propos de Fortrea

Fortrea (Nasdaq : FTRE) est l’un des principaux fournisseurs mondiaux de solutions de développement clinique et d’accès aux soins pour les patients dans le secteur des sciences de la vie. Nous collaborons avec des sociétés de renom et émergentes, spécialisées dans le domaine biopharmaceutique, des dispositifs médicaux et du diagnostic afin de stimuler l’innovation en matière de soins de santé pour accélérer la mise au point de traitements révolutionnaires pour les patients qui en ont besoin. Fortrea propose des solutions pour la gestion d’essais cliniques de phase I à IV, pour la pharmacologie clinique, pour les essais différenciés axés sur la technologie ainsi que des services après approbation. Les solutions de Fortrea s’appuient sur trois décennies d’expérience couvrant plus de 20 domaines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un réseau solide de centres de recherche. Notre équipe talentueuse et diversifiée d’environ 19 000 personnes travaillant dans plus de 90 pays est dimensionnée pour fournir des solutions ciblées et flexibles à nos clients, partout dans le monde. Obtenez plus d’informations sur la manière dont Fortrea influence le changement, du pipeline au patient, sur Fortrea.com et suivez-nous sur LinkedIn et X (anciennement Twitter) @Fortrea.

Coordonnées de Fortrea :
Jennifer Minx (média) – 919-410-4195, media@fortrea.com
Kate Dillon (média) – 646-818-9115, kdillon@prosek.com
Hima Inguva (investisseurs) – 877-495-0816, Investors@fortrea.com

GlobeNewswire Distribution ID 8981987

Fortrea Anuncia Parceria Baseada em IA com a Medidata para Aumentar a Diversidade dos Ensaios Clínicos

Colaboração utiliza a IA da Medidata para aprimorar o acesso e a participação de diversos grupos populacionais em estudos clínicos

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje uma parceria com a Medidata, uma empresa da Dassault Systèmes fornecedora líder de soluções de ensaios clínicos para a indústria de ciências da vida, para uso dos Medidata AI Intelligent Trials para aumento do acesso a diversos pacientes dos ensaios clínicos conduzidos pela Fortrea.

O uso da Medidata AI pela Fortrea se baseia em uma colaboração existente entre as duas empresas que expande o uso do Medidata Rave EdC, um sistema EdC avançado, robusto e seguro para a o gerenciamento e captura de dados em sites de ensaios clínicos, de pacientes e laboratórios. A Fortrea irá utilizar os recursos dos Medidata AI Intelligent Trials, incluindo dados de viabilidade e diversidade do estudo, para ajudar as biofarmas emergentes e grandes, bem como os dispositivos médicos e empresas de diagnóstico, a atingir metas de inscrição que reflitam as populações mais impactadas por cada doença ou condição do estudo.

“Os recursos de dados e interface da Medidata irão aumentar a nossa capacidade de integrar perfeitamente as diversas populações ao processo de testes clínicos”, disse o COO e Presidente de Serviços Clínicos da Fortrea, Mark Morais. “Estamos muito contentes em trabalhar com a Medidata como parte da estratégia de avanço de dados da Fortrea.”

“A Fortrea e a Medidata compartilham o compromisso de avançar a pesquisa de ensaios clínicos e esta parceria está pronta para remodelar o cenário da diversidade dos ensaios clínicos em todo o mundo”, disse Fareed Melhem, SVP, Medidata AI. “Juntas, nossas soluções apoiam os clientes de ciências da vida a acelerar os cronogramas de estudo e tornar os benefícios das terapias clínicas mais acessíveis a uma faixa diversificado de pessoas.”

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico e acesso ao paciente para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes que precisam delas. A Fortrea fornece gerenciamento de testes clínicos de fase I-IV, farmacologia clínica, soluções de testes com tecnologia diferenciada e serviços pós-aprovação. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada de aproximadamente 19.000 pessoas que trabalham em mais de 90 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para paciente na Fortrea.com e siga-nos no LinkedIn e X (antigo Twitter) @Fortrea.

Contatos da Fortrea:
Jennifer Minx (Mídia) – 919-410-4195, media@fortrea.com
Kate Dillon (Mídia) – 646-818-9115, kdillon@prosek.com
Hima Inguva (Investidores) – 877-495-0816, Investors@fortrea.com

GlobeNewswire Distribution ID 8981987

Axi launches Select Your Edge campaign with Manchester City stars

Broker enlists Man City stars to introduce their new capital allocation programme, Axi Select

SYDNEY, Australia, Nov. 20, 2023 (GLOBE NEWSWIRE) — Leading online FX and CFD broker Axi has launched their new campaign, Select Your Edge. Featuring stars of Manchester City FC, the campaign introduces Axi’s new capital allocation programme, Axi Select.

Since 2020, Axi, the Official Online Trading Partner of Manchester City, has utilised their access to the club’s players to deliver engaging content and to highlight their unique offerings. This year, Manchester City stars Erling Haaland, Kyle Walker, and Rodri compete head-to-head for the edge in various challenges such as ball-sorting and tower building.

Hannah Hill, Head of Brand and Sponsorship at Axi, expressed her enthusiasm for their new campaign, stating, “As with every year, working with the City players was, once again, very exciting. They displayed amazing chemistry with each other, and this made for some great banter and amazing content. The collaboration was a unique way to introduce our latest offering, Axi Select. With our new programme, our clients can access the competitive edge they need to become pro traders.”

In September, the broker proudly launched their new capital allocation programme, Axi Select. Aimed to empower ambitious traders and facilitate their progression into professional trading, the programme offers traders the opportunity to access capital funding up to $1,000,000 USD, as well as other exceptional advantages including zero registration fees, and the potential to earn up to 90% of their profits.

Talking about Axi Select when it debuted, Louis Cooper, Chief Commercial Officer at Axi, said, “At Axi, we take pride in being a brand that consistently brings the edge to life for our customers. Our revolutionary new offering, Axi Select, is the first-of-its-kind among brokers and another true reflection of our brand promise. With Axi Select, we deliver unparalleled opportunities to our traders whilst both redefining the boundaries of what’s possible in trading and reshaping the evolution of the financial industry.”

For more information about Axi Select, visit https://www.axi.com/int/funded-trader-programme.
Watch video https://www.youtube.com/watch?v=eDZeNJGi_UU

About Axi

Axi is a global online FX and CFDs trading broker. As the preferred broker for thousands of ambitious customers in over 100 countries worldwide, we help all types of traders, trading businesses, banks and financial organizations find the edge they need to achieve their financial goals through informed transactions made on the world’s financial markets. Axi offers a comprehensive range of assets including CFDs for several asset classes such as Forex, Shares, Oil, Precious Metals, Coffee, Indices, and other commodities.

For other Axi communications, visit https://www.axi.com/int/blog/company-news

For enquiries contact service@axi.com

GlobeNewswire Distribution ID 300957174